Refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T) has been considered a provisional subtype within the diagnostic entity of myelodysplastic syndrome/myeloproliferative disorder diseases (MDS/MPD). As JAK2 V617F mutation is present in a significant proportion of RARS-T patients, 1 many investigators consider this entity to be more closely related to classical MPD. However, a significant minority of patients with RARS-T do not harbor a JAK2 V617F mutation. These patients may have acquired other mutations described in MPD, such as MPL W515L/K 2,3 or may represent RARS cases with other thrombocytosis-inducing conditions. We have previously described an aberrant STAT5 phosphorylation pattern that may Letters to the Editor be an indicator of dysregulation in signal-transduction pathways involved in the pathogenesis of MPD.
1
In addition to phospho-STAT5 immunohistochemistry, cytogenetics may aid the diagnosis of MPD/MDS diseases. Recently, we have described the application of singlenucleotide polymorphism array (SNP-A) 4 as an important tool that can increase the diagnostic value of metaphase cytogenetics (MC) in MDS and MDS/MPD. In particular, SNP-A allows detection of uniparental disomy (UPD), a mechanism for obtaining loss of heterozygosity (LOH) that can affect multiple chromosomes noted to be remarkably frequent in MDS/MPD patients. 4 UPD9p is an example of such a lesion in MPD and explains a mechanism for the occurrence of biallelic JAK2 V617F mutation. We have shown that SNP-A can replace the cumbersome microsatellite analysis used initially to identify UPD9p allowing efficient detection of this and other areas of UPD in MPD and other related conditions. 4 In general, identification of UPD loci may facilitate discovery of candidate genes contained in the commonly affected areas of copy-neutral LOH that are at risk for biallelic mutations, including FLT3 (UPD13q) and RUNX1 (UPD21q) among the most instructive examples.
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We have studied patients with RARS-T with and without a JAK2 V617F mutation to determine whether SNP-A can be used to identify a molecular signature of RARS-T. Based on hypothesis that STAT5 phosphorylation is pathognomonic of true RARS-T, we identified RARS-T patients with aberrant phospho-STAT5 expression. Using a combination of MC, SNP-A, mutational analysis and immunohistochemistry, we set to devise a diagnostic algorithm to clarify the molecular pathogenesis of RARS-T.
A group of 18 patients with phenotypic features consistent with RARS-T (Figure 2a ) was subjected to MC and SNP-A analysis. All these patients showed the presence of ringed sideroblasts, some degree of reticulin fibrosis and varying degrees of thrombocytosis. SNP-A facilitated detection of previously cryptic lesions; 9 of 17 patients showed an abnormal SNP-A-based karyotype (five of these defects were also detected by MC). The new lesions seen by SNP-A included gains of chromosome 11p, 20q and 21q; deletion of 2p and various areas of UPD including 9p, 6p, 2p and 8p (Figure 2a ). Most significantly, UPD1p was found in four patients (Figures 1 and 2a) .
The UPD1 and UPD9 are because of somatic events and constitute clonal lesions as described previously for UPD. 4, 6 The somatic nature of UPD1 in our patients was confirmed by the presence of normal non-clonal cells without UPD1 in the tested sample or in the patient's CD3 lymphocytes.
JAK2 V617F mutation was present in 8 of 18 patients with RARS-T. By SNP-A, UPD9p was found in one patient, which was consistent with the presence of wild-type JAK2 and biallelic JAK2 V617F clone (Figure 1b , right panel). All these patients showed a characteristic nuclear phospho-STAT5 staining pattern in megakaryocytes (Figure 1b, left panel) .
UPD1p was found in four patients with RARS-T, of whom two showed positive phospho-STAT5 immunohistochemistry (Figures 1 and 2a) . The commonly involved region of UPD1p includes the Mpl gene. By analogy to UPD9p and its association with the Jak2 gene, we have hypothesized that the corresponding patients may harbor a MPL W515L mutation. ARMS-PCR followed by confirmatory sequencing indeed showed a mutation in two of four patients with UPD1p, consistent with homozygous MPL W515L mutation. In the context of UPD1, presence of MPL W515L mutation implies that UPD1 is unlikely of germ line origin, in such a case, UPD1 would be associated with heterozygous mutation. An additional patient without UPD1p showed a monoallelic MPL W515L mutation. One patient harbored UPD1p, spanning the Mpl locus (1p35.1-pter), which was not associated with MPL W515L (Figure 2a) , suggesting that other genes located in this region, but not involved in STAT5 activation may be implicated. To date, two singular MPL W515L mutations in two cases of RARS-T have been described in two reports. 7, 8 None of the patients, including two patients with UPD1p, showed MPL W515K mutation. Of note, one patient showed both biallelic MPL W515L and wild-type/biallelic JAK2 V617F mutations (Figures 1a, right panel, and 2a) and demonstrated at least four genetic events during disease initiation and progression: acquisition of an unidentified mutation leading to the development of RARS, with subsequent acquisition of an additional mutation leading to thrombocytosis. In this instance, given the level of the mutant allele burdens, this will have been the MPL W515L (first as a monoallelic mutation, and then a bialleleic mutation as the result of UPD). Subsequently, it would appear that a proportion of cells acquired a JAK2 V617F mutation, and there may well have been another round of mitotic recombination (this time involving chromosome 9) to produce JAK2 V617F-homozygous cells.
JAK V617F or MPL W515L mutation analysis (8 of 12 cases) ( Figure 2 ) was predictive for the presence of phospho-STAT5 analyzed by immunohistochemistry. One phospho-STAT5-positive patient showed an inv(3)(q21q26.2) possibly explaining thrombocytosis and STAT5 activation. Given the strong association with mutations in genes involving the STAT5 pathway, we believe that the three remaining patients with otherwise classical RARS-T may harbor as yet undiscovered molecular lesions involving STAT5 signaling.
Activating mutations of JAK2 V617F or MPL W515L were not found in any of the patients negative for phospho-STAT5 staining. One of these patients had UPD1p, in addition to other genetic lesions consistent with the diagnosis of MDS and not commonly associated with STAT5 activation. The remaining three patients are also pathogenetically related to MDS, but their thrombocytosis may be a coincidental rather than an MPDassociated molecular lesion (Figure 2a) . In summary, current molecular methods allow the detection of JAK2 V617F and MPL W515L mutations in a significant proportion of RARS-T patients, explaining their phenotype. Phospho-STAT5-positive cases that represent otherwise typical RARS-T, lacking JAK2 V617F or MPL W515L, should be investigated for additional abnormalities in this pathway. Phospho-STAT5-negative patients showed typical features of myelodysplasia, for example, del(5), þ 8 and partial loss of chromosome X, which likely exclude the presence of known STAT5-activating mutations and may best be considered MDS origin. To our knowledge, this is the first description of biallelic MPL W515L mutation and UPD1p found in RARS-T patients, which is important for the understanding of the selection process and pathophysiology of activating mutations in MPD. While detection of UPD1 or UPD9 does not add to the diagnostic algorithm, nevertheless our current and other studies in MDS and acute myeloid leukemia clearly indicate that SNP-A karyotyping improves/complements MC and allows detection of additional lesions. The occurrence of homozygous mutations as a result of UPD indicates that acquisition of biallelic mutations constitutes a positive selection factor leading to copy-neutral LOH. Other mechanisms, including haploinsufficiency or inactivating mutations of tumor-suppressor genes, may lead to selection of clones containing LOH due to loss of chromosomal material.
Letters to the Editor Translocations involving the immunoglobulin heavy chain locus (IGH@) are common abnormalities in lymphoma and mature B-lineage acute lymphoblastic leukaemia (ALL) 1 and more recently in B-cell precursor ALL (BCP-ALL). [2] [3] [4] In most cases, IGH@ translocations result in the transcriptional activation of an oncogene.
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1 We report here a reciprocal translocation, t(14;19)(q32;p13), that juxtaposes the erythropoietin receptor precursor (EPOR) at 19p13 to the IGH@ enhancer resulting in its overexpression.
Cytogenetic analysis identified a reciprocal translocation between chromosomes 14 and 19, t(14;19)(q32;p13), in two patients with BCP-ALL who were registered on the Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute leukaemia 5 ( Figure 1a) . It was the sole chromosomal abnormality in patient no. 4860. In contrast, the karyotype of patient no. 10 672 showed two sidelines; one with the translocation, t(9;15)(q1?;q1?), and the other with a deletion of the short arm of chromosome 9 accompanying the t(14;19)(q32;p13). The two patients were different with respect to their clinical features (Table 1) . Patient no. 4860 received a bone marrow transplant (BMT) 5 months after diagnosis; he currently remains in complete remission 48 months after transplant. Patient no. 10 672 suffered a bone marrow relapse 6 months after diagnosis followed by BMT 4 months later. She remains alive at 13 months after diagnosis.
Cytogenetics and fluorescence in situ hybridization (FISH) were performed on the same fixed cells prepared from all samples. The involvement of IGH@ was determined by interphase FISH, using an IGH@ dual-colour break-apart rearrangement probe (Figure 1b) as described earlier.
2 This probe gave a positive result in both patients (Table 1 and Figure 1b ). All three remission samples for patient no. 10 672 had a normal signal pattern. In her relapse sample, the reappearance of the translocation was indicated by the presence of the same split signal pattern as seen at diagnosis in 62% of nuclei. FISH mapping of 19p in patient no. 10 672 identified EPOR as the IGH@ partner gene, confirmed by a home-grown dual-colour break-apart rearrangement probe in metaphase (Figures 1c and d) . A split signal pattern was observed in interphase nuclei from the diagnostic samples of both patients and the relapse sample of patient no. 10 672 (Table 1) , confirming the involvement of EPOR at both diagnosis and relapse.
Cloning by long-distance inverse PCR (LDI-PCR) (carried out as described earlier) 2 in patient no. 4860 identified the breakpoint on chromosome 14 to be within the IGHJ4 gene segment, whereas the breakpoint on 19p was located approximately 3 kb centromeric of EPOR at genomic location 11,359,017 (Figure 1d ). The different breakpoints within IGH@ in patient no. 10 672 could not be cloned using the LDI-PCR primers available. However, quantitative real-time PCR (qRT-PCR) studies were carried out on RNA samples from this patient. A greater than 230-fold increase in the expression of EPOR was observed in the diagnostic sample (Figure 1e ). Three , CISH (assay ID Hs_00367082) and PIM-1 (assay ID Hs_00171473). The endogenous control gene, B2M (assay ID Hs_99999907), was used to normalize the results of both patients and controls (Applied Biosystems, Foster City, California, USA). Expression levels were compared with the expression in four ALL patients without the translocation. Two patients with other IGH@ translocations, a patient with high hyperdiploidy, normal salivary gland and bone marrow (positive control for EPOR expression because of the presence of erythroid RNA, which is absent from patient samples from which the red blood cells have been removed as part of the preparation procedure) RNA (BD Biosciences, Oxford, UK) were used as controls.
